Bitter pill for Ranbaxy: SC notice on quality concerns

PIL also seeks action against drug regulator for letting a FDA-censured firm continue operations

pankaj

Pankaj Kumar | March 14, 2014



Ranbaxy faced another setback on Friday as the supreme court issued notice to the leading drugmaker as well as the central government following a PIL that seeks cancellation of the firm’s licence and a CBI probe into the allegedly sub-standard quality of its medicines.

"The matter requires consideration and we will examine it but we cannot grant any interim stay," a bench headed by chief justice P Sathasivam said.

The PIL was filed by advocate ML Sharma, pointing out that Ranbaxy was fined $500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs last year. The PIL demanded court to stop production from the manufacturing units in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.

Read more about Ranbaxy’s travails:

Dirty medicine: Ranbaxy's FDA travails



Sharma sought action against the drug regulator, Central Drug Standards Control Organisation (CDSCO), for granting permission to Ranbaxy to sell drugs in India though the firm has faced a series of strictures from the US FDA.

Read interview with drug controller GN Singh:

"Ranbaxy has been asked to comply with regulations"

Comments

 

Other News

How Rafi, Raj Kapoor helped pave the way for a great uranium deal

There`s a certain moment in diplomacy that`s too personal to be captured in a communiqué, too small to make the front page, but more revealing than the front page. This week, prime minister Narendra Modi reached Tashkent and, amid the pomp of state visits, managed to evoke the old Bollywood tunes

Distinguishing Fish 1 and Fish 2: The pragmatism behind India’s WTO ratification

 India became the 123rd WTO member to ratify the multilateral Agreement on Fisheries subsidies (AoFS) when it deposited the Instrument of Acceptance for Phase 1 on July 20, 2026. The ratification is restricted to disciplining Illegal, Unreported and Unregulated fishing (IUU), protection for overfished

The 7% growth problem: Why the next 7% will be harder

India has become accustomed to hearing the 7% growth number. It is now less a milestone than an expectation. Yet the paradox is becoming clearer: maintaining 7% growth may be considerably harder than achieving it once. India’s real GDP grew 7.7% in FY2025–26, following growth of 6.5% in FY202

The Constitution cannot be altered: Justice Abhay Oka

Justice Abhay Oka, who retired from the Supreme Court in May 2025, has said that the Constitution of India cannot be altered. Explaining the landmark Kesavananda Bharati judgment (1973) on the basic structure of the Constitution, he said, “This is one judgment that has saved democracy in India.&rdq

How the flora and fauna evolved in the Indian subcontinent

Mammals of India  By A.J.T. Johnsingh and P.O. Nameer HarperCollins India in association with Bombay Natural History Society  

India`s renewable race is moving beyond megawatts

When Shell bought Sprng Energy in 2022, India`s renewable energy market appeared to offer precisely what global energy majors were seeking: scale, growth and a place in one of the world`s largest energy transitions. Four years later, Shell is selling the same business to Aditya Birla Group for an enterpris

Upcoming Conferences



-->

Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter